BridgeMD
New treatment option for Obesity
Official title Feasibility of Semaglutide in Advanced Lung Disease
ClinicalTrials.gov ID: NCT05746039
What this study is testing
What is Semaglutide Pen Injector?
Semaglutide Pen Injector is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for obesity.
Also referred to as Ozempic.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question(s) it aims to answer are: 1.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary...
- Age \> 18
- BMI \> 30 kg/m2
- Requires supplemental oxygen on exertion
- Stable treatment regimen X 90 days
You likely can't join if
- Diabetes
- Pregnant or Breastfeeding
- Recent weight loss
- Recent or chronic GI complaints
- History of gastroparesis
- History of scleroderma
See the full eligibility criteria
- Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension
- Age \> 18
- BMI \> 30 kg/m2
- Requires supplemental oxygen on exertion
- Stable treatment regimen X 90 days
- Use of disease-modifying therapy
- Diabetes
- Pregnant or Breastfeeding
- Recent weight loss
- Recent or chronic GI complaints
- History of gastroparesis
- History of scleroderma
- Hospitalized at time of evaluation
- Use of weight loss medication in last 90 days
- Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)
- Uncontrolled thyroid disease
- History of acute/chronic pancreatitis
- Prior suicide attempt
- Suicidal ideation in last 90 days
- Presence of a pacemaker or defibrillator
The study team makes the final eligibility decision.
Where it's taking place
- Philadelphia, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.